INTRODUCTION {#S7}
============

Recent guidelines have recommended that 2-3 days per week of moderate to vigorous physical activity may be necessary to attenuate secondary comorbidities after spinal cord injury (SCI) \[[@R1]\]. However, the guidelines did not address the extensive muscle atrophy and how this may accelerate the risks of developing secondary comorbidities \[[@R2]--[@R5]\]. Resistance training (RT) has been shown to be an effective rehabilitation approach in mitigating muscle atrophy, infiltration of intramuscular fat (IMF), evoking muscle hypertrophy, and improving the metabolic profile in healthy individuals, elderly populations and in persons with SCI \[[@R6]--[@R14]\]. Such changes are likely to reduce the heightened risks of developing serious health consequences including cardiovascular disease and type II diabetes \[[@R4], [@R5]\]. In persons with motor complete (AIS A or B) SCI (i.e. unable to voluntary contract their muscles below the level of injury), electrically evoked RT using neuromuscular electrical stimulation (NMES-RT) resulted in a robust muscle hypertrophy for the trained knee extensor \[[@R7],[@R11],[@R12]\]. One study demonstrated 40% increase in skeletal muscle size following 12 weeks of NMES-RT in persons with SCI \[[@R8]\]. Another study demonstrated an increase in whole thigh, knee extensor and flexor cross-sectional area (CSA) by 28%, 35% and 16%, respectively, following 12 weeks of NMES-RT \[[@R7]\]. These studies used Dudley's protocol that relied on progressively loading the paralyzed muscle twice weekly using NMES and ankle weights \[[@R10]\]. The combinatory effect of 16 weeks of NMES-RT in conjunction with low-dose testosterone replacement therapy (TRT) on cardio-metabolic risk factors was recently completed \[[@R11]\]. Low-dose TRT and electrically evoked RT resulted in 43% hypertrophy of the trained knee extensors, 14-17% increase in basal metabolic rate and decrease in visceral adiposity compared to TRT only \[[@R11]\].

Previous studies using electrically evoked RT have been directed toward knee extensors considering the extensive muscle atrophy that may exceed 40-50% of the original muscle size \[[@R2],[@R3]\]. Progressive RT programs have also been shown to promote hypertrophy of the surrounding untrained muscle groups \[[@R12], [@R13]\]. However, it is still unclear whether NMES-RT of the knee extensors may induce similar hypertrophy of the untrained muscles (i.e. not directly exposed to electrical stimulation) in persons with SCI. This is highly important considering the wide spectrum of complications associated with muscle atrophy in the lower extremities including blood clotting, venous pooling \[[@R15]\] and sacral pressure injuries following changes in the size and the quality of the glutei muscles \[[@R16], [@R17]\]. Furthermore, Abilmona and Gorgey noted that increases in trunk muscle CSA may be associated with decreases in visceral adiposity and improvement in the metabolic profile of persons with SCI \[[@R18]\]. Therefore, it is possible to hypothesize that an increase in lower leg, glutei and trunk muscle CSAs could attenuate several of the aforementioned complications.

In attempt to test this hypothesis, the effect of electrically evoked RT on the untrained trunk muscles was previously conducted \[[@R12]\]. The hypothesis was based on the fact that the untrained trunk muscles have close proximity to the NMES current, anatomically serving as stabilizers during NMES-induced leg extension or may be responsive to increased circulating insulin growth factors \[[@R7],[@R12]\]. The findings indicated that NMES-RT resulted in hypertrophy of knee extensors, flexors, and hip adductors but without changes in the trunk muscles following 12 weeks of training \[[@R12]\]. A possible explanation is the short duration of application (12 weeks) and limited endogenous growth factors that may maximize applications of NMES-RT on untrained muscles.

Persons with SCI suffer an average 43% decline in serum testosterone levels. Low serum testosterone (\< 325ng/dL) has been observed in 40-60% of men with SCI \[[@R19]--[@R21]\]. Recently, strong associations were noted between serum testosterone and cardio-metabolic risk factors in persons with SCI \[[@R20]\]. High circulating testosterone is associated with increased leg lean mass, thigh muscle CSA and decreased visceral adiposity \[[@R20]\]. In fact, those with low-levels of circulating testosterone have 72% greater visceral adiposity than those with normal testosterone \[[@R20]\]. TRT has been shown to be a safe and effective strategy in improving lean tissue mass and basal metabolic rate in men with SCI \[[@R21], [@R22]\]. Therefore, the addition of low-dose TRT may maximize the effects of NMES-RT on the proximal (trunk and glutei) and distal (lower leg) untrained muscles during training of the knee extensor muscle group.

Therefore, we have expanded the analysis on recently published work to investigate the effects of low-dose TRT and NMES-RT on untrained muscles \[[@R11]\]. The primary objective of the current pilot study was to examine the additive effect of low-dose TRT to NMES-RT for 16 weeks on the untrained trunk, glutei and lower leg muscles compared to TRT only in persons with motor complete SCI. Our hypothesis was that the addition of testosterone would amplify the effects of NMES-RT on the CSAs of untrained muscles (lower leg, glutei and trunk) when compared to TRT only in persons with chronic motor complete SCI.

METHODS {#S8}
=======

Participants {#S9}
------------

Twenty-two men with chronic (≥ 1-year post injury) motor complete (AIS A or B) SCI between the ages of 18 and 50 participated in the current study (NCT01652040). Recruitment started in August 2012 and ended in April 2015 after meeting the target sample size \[[@R14]\]. Inclusion/exclusion criteria have previously been published in detail elsewhere \[[@R11],[@R14]\]. After providing written consent which was approved by a local ethics committee, a physical examination was conducted on each subject by a certified physician. Participants were then randomized in a blinded manner into one of two groups either TRT and NMES-RT (TRT+RT) or TRT only for 16 weeks ([Table 1](#T1){ref-type="table"}).

Magnetic resonance imaging (MRI; 1.5T; General Electric) was performed at baseline (BL, week 0) and post intervention (PI, week 17) of the trunk, glutei and lower leg muscles. MRI images were captured to measure the CSA of specific muscle groups and intramuscular fat (IMF) within each muscle group (i.e. absolute muscle CSA). The recently published primary outcomes of the clinical trial were knee extensor and whole thigh muscle CSA \[[@R11]\]. Three untrained muscle group CSAs (trunk, glutei and leg) were considered secondary outcome variables of the current study (see [table 2](#T2){ref-type="table"}). The trunk muscle group included six individual muscles (see below), the glutei group included the total glutei, gluteus maximus and gluteus medius muscles and the lower leg included the soleus, gastrocnemius and tibialis anterior muscles.

Interventions {#S10}
-------------

### Testosterone Replacement Therapy (TRT) {#S11}

Each participant received a low-dose of 2-6 mg/day of testosterone administered through transdermal testosterone patches (Androderm; Watson Pharma, Parsippany, NJ) and alternated between both shoulders \[[@R11], [@R14]\]. Participants were instructed to place the patches before bedtime on dry skin and to temporarily remove patches during bathing. Baseline measurements of serum testosterone were used to determine initial dosages, and subjects with \<300, 300-600, or \>600 ng/dL received 6, 4 or 2 mg/day dosages respectively. Participants or caregivers were instructed to count the used patches and provided a log-form to report adherence on a monthly basis to the study team. Monthly measurements of serum testosterone were monitored in a blinded fashion by an endocrinologist to adjust for the dose. If the participant's serum testosterone levels exceeded 1000 ng/dL during testing, a decreased dosage of 2 mg/day was recommended. Participants with serum testosterone concentrations \<250 ng/dL received reeducation regarding their procedure for administering TRT and whether the patches were placed correctly or not.

### Resistance Training (RT) {#S12}

Participants randomized in the TRT+RT group received progressive resistance exercise of the knee extensor muscle groups \[[@R10]--[@R14]\]. Twice weekly for the 16-week period, a research team member conducted exercise sessions for both lower extremities starting with the right leg and followed by the left leg. Blood pressure and heart rate were monitored through the entire session. Electrical stimulation was administered using large (8x10 cm) electrodes that were placed laterally on the proximal thigh and medially on the distal thigh. Participants remained in their wheelchair while their knee extensors were stimulated through manually adjusted NMES current (Theratouch 4.7; Richmar, Inola, OK; Biphasic waveform, 30 Hz, 450 μs pulse width, current intensity enough to elicit full knee extension) for 4 sets of 10 repetitions. During the first week, no ankle weights were used during training. If the participant completed all exercise sets without fatigue, weights were increased in 2-pound increments. Progression in current amplitude and ankle weights were recorded and monitored throughout the 16-week intervention \[[@R11]\].

Magnetic Resonance Imaging {#S13}
--------------------------

Participants were stationed in a supine position with their lower extremities strapped to minimize spontaneous involuntary movements due to muscle spasms. Images were captured with Echelon RAPID Torso/Body Coil (Hitachi Medical Systems America, Twingsburg, OH). The technician ensured that lower portion of the coil was placed at the symphysis pubis both BL and PI for each participant \[[@R18], [@R20]\]. A fast spin-echo sequence was used to perform T1-weighted imaging (axial in-phase (IP) /out-phase (OP) with a repetition time of 140 ms and echo time of 4.2 and 2 ms for the IP and the OP, respectively; a 42-cm field of view, matrix size of 256 x 256, one NEX and acquisition time of 40 seconds) to measure trunk and glutei muscles. Transverse slices were acquired from the xyphoid process to the femoral heads (0.8 cm thick, 0.4 cm apart) \[[@R7], [@R11], [@R18], [@R20]\]. A series of two stacks were acquired, using L4-L5 as a separating point. The umbilicus was located to identify the intervertebral space between L4 and L5 after acquisition of a localizer sequence. To reduce respiratory-motion artifact, participants were asked to inhale deeply and hold their breaths for 10-15 seconds. Two sets of 9-12 slices were captured, the first set extended superiorly from L4-L5 to the xyphoid process and the second set extended distally from L4-L5 to the femoral heads \[[@R7], [@R11], [@R18], [@R20]\].

To capture bilateral lower leg muscles, transaxial images (8 mm thick, 15 mm apart) were captured from the knee to the ankle joints using a localized GE body array flex coil to ensure an adequate signal-to-noise ratio and higher image resolution (repetition time, 850-1,000ms; echo time, 6.7ms; field of view, 20cm; matrix, 256×256) \[[@R15]\]. The coil was placed at the proximal border of the patella and extended to cover the entire leg \[[@R15]\].

Images were analyzed in a blinded fashion to the group assignment using a specialized imaging software (Win Vessel 2, Ronald Meyer, MSU, MI, USA). Using Image J-software, images were matched between BL and PI based on bony landmarks. Images were automatically segmented into fat, skeletal muscle and background/bone (high, mid and low intensity, respectively). To correct for intensity variations caused by radio frequency heterogeneity, a first pass segmentation was used. The corrected image was then re-segmented to the three intensity components using a fuzzy c-mean clustering algorithm \[[@R3], [@R11]\]. For each selected image, the anatomical region of interest was manually traced pixel-by-pixel to quantify CSA (cm^2^). Absolute IMF CSA was then quantified using a bimodal histogram at the midpoint between the muscle and fat peaks \[[@R3],[@R11],[@R15]\]. Each muscle group was presented as total CSA (muscle CSA without subtracting IMF) and absolute muscle CSA (muscle CSA after subtracting IMF).

### Trunk Muscles {#S14}

Six to seven images were selected between the upper lobes of the kidneys and the top of the iliac crest \[[@R12],[@R18]\]. The images were selected to cover the primary trunk muscles as has been previously indicated \[[@R12],[@R18]\]. The muscles that were manually traced are presented in [Figure 1C](#F1){ref-type="fig"}, and include the erector spinae (ES; 1), multifidus (MF; 2), quadratus lumborum (QL; 3), iliopsoas (PS; 4), rectus abdominis (RA; 5) and the external and internal obliques (EIO; 6) \[[@R18]\].

### Glutei Muscles {#S15}

Four images were selected between the iliac crest and the top of the femur. The images were selected based on anatomical distinction of the boundaries of the glutei muscles and overall image quality. The left or the right glutei were analyzed based on optimal quality of the signal intensity. The muscles that were manually traced and analyzed are presented in [Figure 1A](#F1){ref-type="fig"} and [B](#F1){ref-type="fig"}. These include the gluteus maximus (GMX; A1), gluteus medius (GMD; A2) and total glutei (GTOT= GMX+ GMD+ gluteus minimus; B). Muscle CSA and IMF CSA values were averaged across all four images.

### Lower Leg Muscles {#S16}

Twelve to fifteen images were selected between the knee and the ankle joints based on image quality. The regions that were manually traced are shown in [Figure 1D](#F1){ref-type="fig"} and include the tibialis anterior (TA; 1), soleus (SOL; 2), gastrocnemius (GAS; 3), and total leg muscles (TLM; entire traced region excluding bone). The leg selected for analysis was determined based on the side chosen for glutei analysis. The analyzed images of the leg muscles were divided equally into three groups (proximal, middle and distal) CSAs and the slices within each group was then averaged.

Data Analysis {#S17}
-------------

Participant characteristics were summarized using means and standard deviations or frequencies or percentages. All data are presented as mean ± standard deviation (SD). Separate means and standard deviations of each of the cardio-metabolic risk factors were summarized by treatment group and time. To determine within time (BL vs. PI) and between group (TRT+RT vs. TRT only) differences, a 2 x 2 repeated measures ANOVA tests were performed. This model included fixed effects for both factors, as well as the interaction, and a random effect to account for dependence between the measures for a single individual. Statistical significance was set at α less than 0.05 and due to the secondary focus of these outcomes in the clinical trial, no multiple adjustment correction was made \[[@R23]\]. The statistical software package R (v3.4.1) was used to perform all statistical analysis.

RESULTS {#S18}
=======

Participant Characteristics {#S19}
---------------------------

The results presented are a follow-up analysis to our recently published work examining the effects of low-dose TRT+RT vs. low-dose TRT only on cardio-metabolic risk factors in persons with SCI \[[@R11]\]. All participants received low-dose TRT from 2-6 mg per day for 16 weeks and serum testosterone levels increased from 413.5-525 ng/ dl in both groups \[[@R11]\]. There were no significant differences in the physical characteristics between the TRT+RT and TRT groups (*P*\> 0.1; [Table 1](#T1){ref-type="table"}). One participant in the TRT+RT group withdrew in week 8 due to recurring episodes of syncope, therefore PI MRI images were not captured. In the TRT only group, MRI was not captured in one participant due to the existence of remaining bullet fragments in his spine. Another two participants in the TRT group lacked optimal quality images of the glutei and lower leg muscles, therefore analysis was not performed. Glutei IMF data for two participants, one in the TRT+RT and one in the TRT group, were not measured due to poor signal intensity quality; which resulted in difficulty separating pixels of the muscles from those of IMF.

### 1.. Trunk Muscles {#S20}

[Table 2](#T2){ref-type="table"} summarizes the CSAs of the trunk muscles in the TRT+RT and TRT only groups at BL and PI with 95% CI. TRT+RT and TRT only did not induce changes (*P*\>0.05) in muscle CSAs of any of the trunk muscles \[ES, MF, QL, IP, RA and EIO\]. Furthermore, there was no difference between groups. However, notable differences in the change scores were observed between TRT+RT and TRT for QL (*P* =0.078) and EIO (*P* =0.093).

### 2.. Glutei Muscles {#S21}

[Table 2](#T2){ref-type="table"} displays the CSAs of total glutei, absolute glutei (i.e. after subtracting IMF) and IMF CSAs at different time points (BL and PI) following both interventions (TRT+RT vs. TRT only), with the mean between group differences and 95% CI for each individual muscle.

#### a.. Total and absolute gluteus maximus muscle {#S22}

Total gluteus maximus CSA increased by 14% (*P*= 0.003) in the TRT+RT group; however, there was no changes in the TRT group (*P* =0.555; [Figure 2A](#F2){ref-type="fig"}). TRT+RT resulted in a nominally greater increases in the gluteus maximus CSA with a mean difference of 2.59 cm^2^ compared to TRT only \[95% CI: \--0.04, 5.24 cm^2^; *P*= 0.072\]. There was a 16% increase in absolute gluteus maximus for the TRT+RT group (*P*= 0.001) with little to no change in the TRT group (*P* =0.496; [Figure 2B](#F2){ref-type="fig"}). TRT+RT produced a greater increase (*P*=0.044) in absolute gluteus maximus m. compared to TRT only group with a mean between group differences of 2.86 cm^2^ and 95% CI: 0.30, 5.45 cm^2^. However, gluteus maximus IMF did not change in either intervention.

#### b.. Total and absolute gluteus medius muscle {#S23}

A 10% increase in the total gluteus medius CSA was observed for the TRT+RT group (*P*= 0.001) but not for the TRT group (*P*=0.372). TRT+RT produced a greater increase (*P*=0.042) in total gluteus medius m. compared to TRT only group with a mean between group differences of 1.89 cm^2^ and 95% CI: 0.23, 3.58 cm^2^.

The absolute gluteus medius CSA increased by 14% in the TRT+RT group (*P*= 0.006), but not for the TRT group (*P* =0.173). No differences in absolute glutes medius CSA were observed between both groups (*P* =0.153) ([Figure 2D](#F2){ref-type="fig"}).

#### c.. Total and absolute whole glutei muscle {#S24}

Total glutei m. increased (*P*= 0.02) for both groups from BL to PI with an interaction between the TRT+RT and the TRT groups (*P*= 0.04). The TRT+RT group showed an 8% increase (*P*= 0.01) in the total glutei CSA ([Figure 2E](#F2){ref-type="fig"}). TRT+RT produced a greater increase (*P*=0.035) in total glutei m. compared to TRT only group with a mean between group differences of 5.27 cm^2^ and 95% CI: 0.90, 9.69 cm^2^.

Absolute total glutei CSA increased (*P*= 0.004) for both groups from BL to PI. Absolute total glutei CSA increased by 11% (*P*= 0.005) for the TRT+RT group, but there were no changes in the TRT group (*P*=0.3; [Figure 2F](#F2){ref-type="fig"}). There was a trend towards an interaction between the two groups (*P*= 0.09). TRT+RT produced a nominal increase (*P*=0.09) in absolute glutei m. compared to TRT only group with a mean between group differences of 4.56 cm^2^ and 95% CI: −0.23,9.42 cm^2^.

### 3.. Lower Leg Muscles {#S25}

The CSA values for the leg muscles are summarized in [Table 2](#T2){ref-type="table"} for the TRT+RT and TRT groups at BL and PI. There were no observed differences between the two groups and changes from BL to PI following either TRT+RT or TRT for the proximal, middle and distal tibialis anterior m., soleus m., gastrocnemius m. and total leg muscle.

DISCUSSION {#S26}
==========

The major findings of this secondary pilot study indicated that the addition of low-dose TRT to RT induced hypertrophy of non-targeted untrained glutei muscles. Mean between group differences suggested that TRT+RT resulted in greater increases in glutei m. CSA compared to the TRT only. Although trunk muscles were not significantly affected, a trend towards an interaction between the two groups for the QL and EIO may indicate that these muscles are positively affected in the TRT+RT group compared to the TRT only group. Neither TRT+RT nor TRT alone increased CSA of the untrained lower leg muscles. Furthermore, the combined application of RT and low-dose TRT may be recommended as a future prophylactic intervention for the prevention of pressure injuries and improvement of body composition because of its positive effects on the trained as well as untrained muscle groups.

Rationale of studying untrained muscles {#S27}
---------------------------------------

The rationale of studying the untrained muscles was based on previous work that demonstrated the effects of unilateral RT on contralateral untrained muscles \[[@R24]\]. We have previously shown that 8 weeks of unilateral NMES-RT did not result in contralateral muscle hypertrophy of the untrained knee extensor muscle group \[[@R13]\]. The concept of evoking muscle hypertrophy in untrained muscles may be beneficial to those with sacral ulcers greater than grade II, in which sitting may induce shear stress or direct applications of electrical stimulation on the exposed ulcer may not be feasible. Biomechanically, it is also difficult to load the hip extensors to evoke hypertrophy because of the long lever arm of the lower extremity and difficulty of attaining prone position for extended period after SCI.

Potential mechanisms of evoking hypertrophy in the untrained muscles {#S28}
--------------------------------------------------------------------

The mechanism behind hypertrophy of untrained muscles still remains unclear; however, there are several hypotheses that may explain these findings. During training of the knee extensors, possible bleeding of the electrical current to the glutei muscles may have occurred due to the smaller muscle size after SCI. Additionally, there may be occurrence of a volley phenomenon after using a long pulse duration of 1ms and lead to anti-dromic afferent stimulation of knee extensors \[[@R25]\]. This afferent stimulation may activate the alpha motor neuron pools and lead to indirect stimulation of the adjacent untrained muscle groups. Despite the fact that we used a pulse duration of 450 μs, increasing the current amplitude to stimulate the knee extensors reflexively resulted in noticeable hip flexion and ankle dorsiflexion in several of our participants; suggesting the possibility of anti-dromic volley stimulation of the untrained muscles. Moreover, isometric torque data at 100 mA and 30 Hz suggested the occurrence of the volley phenomenon during examining knee extensor peak torque in response to either intervention (data not shown). Gorgey *et al.* also noted a significant increase in IGF-1 following 12 weeks of NMES-RT in men with SCI. This increase was also associated with hypertrophy of the knee extensors \[[@R7]\]. However, in the current trial, we noticed a decrease in IGF-1 and increase in insulin growth factors binding protein-3 following 16 weeks of training \[[@R11]\]. The discrepancy between both studies may either attribute to the influence of TRT on insulin growth factors or due to the duration of both studies (12 vs. 16 weeks) \[[@R11]\].

Clinical relevance of hypertrophy of the glutei muscles {#S29}
-------------------------------------------------------

Our baseline measurements of gluteus maximums m. agreed with a previous report using CT scans in persons with chronic SCI \[[@R17]\]. Wu et al showed that gluteus maximus m. in persons with SCI was 55% of that of able-bodied controls \[[@R17]\]. Furthermore, the authors highlighted that muscle quality has dramatically changed by increasing infiltration of IMF (SCI: 29% vs. AB: 8%) \[[@R17]\]. Therefore, TRT+RT is likely to reciprocate this profile by increasing glutei muscle size, improving intrinsic tissue health, enhancing regional blood flow and preventing the frequent occurrence of pressure injuries in this population. Dolbow *et al.* studied seat pressure changes in men with SCI after eight weeks of functional electrical stimulation cycling \[[@R26]\]. The study showed a positive trend towards a reduction in ischial seat pressure \[[@R26]\]. Our findings indicate that this trend may result from increasing glutei CSA noted in the current work. Eight weeks of NMES helped to improve tissue oxygenation levels and seating pressure distribution in individuals with SCI \[[@R16]\]. Increases in muscle size may have been the underlying mechanism for previous findings \[[@R16],[@R26]\], as muscle helps to improve surrounding tissue health through increased vascularization and mitochondrial oxygen utilization. These are all critical factors in preventing costly and potentially life-threatening pressure injuries after SCI.

In elderly population, an increase in knee extensor CSA by 5-15% following RT for 6-30 weeks is considered clinically relevant \[[@R27]\]. Wu et al. demonstrated small 5-11% increases in sacral interphase pressures following applications of implanted electrical stimulation system for 5 minutes \[[@R28]\]. Therefore, the increase in glutei muscle CSA (8-16%) is a noteworthy finding, and may lead to a number of important health benefits including increasing tissue interphase pressures and tissue oxygenation in individuals with SCI. We recently showed that 16 weeks of low-dose TRT+RT led to an increase in total and absolute thigh muscle CSA by roughly 20 cm^2^, while no changes in muscle size were noted following low-dose TRT only \[[@R11]\]. Our findings suggest that the addition of RT to low-dose TRT may be beneficial in inducing muscle hypertrophy of the trained thigh muscles and adjacent glutei muscles. Higher serum testosterone in men with SCI is linked to positive body composition \[[@R18]\] and cardiometabolic outcomes \[[@R29]\]. However, low-dose TRT administered in the current study was not enough to induce trunk, glutei or lower leg muscle hypertrophy.

Why study trunk muscles? {#S30}
------------------------

Exercise involving NMES and functional electrical stimulation has primarily focused on the lower and upper extremity muscle groups. Trunk fat-free mass represents 49-51% of total body fat-free mass \[[@R30]\] and is essential for posture, transfers, coughing and breathing \[[@R31]\]. Additionally, trunk muscles have been associated with a positive metabolic profile and negatively related to central adiposity \[[@R18]\]. Gorgey *et al.* investigated the effects of 12 weeks of NMES on the CSA of adjacent trunk muscles and concluded that trunk muscles were not affected by NMES-RT of the thigh muscles \[[@R12]\]. Our results showed a trend towards an interaction between the low-dose TRT+RT and TRT group, which may indicate that the addition of TRT to RT helps to amplify the effects of RT. Bauman *et al*. showed increase in trunk lean mass following 12 months of administering TRT in hypogonadal men with SCI \[[@R22]\]. The lack of robust changes in the size of trunk muscles may be explained by the fact the trunk muscle mass collectively is only 1.2 kg \[[@R30]\] and the large mass of the surrounding visceral and subcutaneous adipose tissue may impede the progression of the current to directly activate them. The current findings may also suggest that direct stimulation of the trunk muscles is necessary to yield muscle hypertrophy in persons with SCI. A future clinical larger scale trial may reveal such interaction noted with the trunk muscles.

MRI as an imaging technique {#S31}
---------------------------

MRI captures multi-axial slices across the entire length of the muscle \[[@R15]\]. This provides robustness of comparing muscle CSA at the same location between BL and PI as well as accurate quantification of absolute muscle CSA after separation of IMF \[[@R3],[@R7]--[@R11]\]. Furthermore, the use of a localized coil improved signal-to-noise ratio and greatly enhance image quality; which further helps in easily matching images based on bony landmarks between BL and PI. The improvement in mage quality, accurate matching of images at different timepoints as well as capturing and analyzing images in a blinded fashion reduce the likelihood of introducing error from using different location or orientation.

Limitations {#S32}
-----------

The age range was only limited to 18-50 years to ensure safety and avoid potential cardiovascular risk consequences that may result from using TRT. Only men were recruited with motor complete SCI (AIS A or B) and women were not enrolled for ethical consideration regarding using TRT.

Because of budgetary constraints, the design of the study did not include NMES-RT only or TRT placebo-controlled groups. The NMES-RT effects on muscle size have been widely studied on the trained knee extensor and untrained trunk muscle groups in persons with motor complete SCI \[[@R7],[@R11]--[@R14]\]. Five different studies have clearly demonstrated 35-40% hypertrophy of the knee extensor muscle group following NMES-RT in persons with motor complete SCI \[[@R7],[@R8],[@R10],[@R11],[@R13]\]. However, NMES-RT was ineffective in evoking changes in the untrained trunk muscles. The rationale behind the current design (TRT+RT vs. TRT only) was to introduce an alternative rehabilitation approach that can promote muscle hypertrophy or increase lean mass in pre-existing medical conditions that may be inadequate to participate in NMES-RT program; because of low tolerance to electrical stimulation with intact sensation below the level of injury, autonomic dysreflexia, pressure ulcers greater than grade II, and peripheral lower motor neuron injury.

Additionally, few participants were not included in the final analysis because of specific precautions regarding using MRI or because of low-image quality. The overall final sample size may have impacted the findings of the current study. A larger sample would be ideal to account for the attrition rate or failure to capture MRI in persons with SCI. It is likely that the trunk muscles were impacted due to the trend towards an interaction between the two study groups, however these results may have been masked by the heterogeneity of our study sample. According to Rankin *et al.*, individuals with tetraplegia have 13% smaller trunk muscle CSA than individuals with paraplegia \[[@R30]\]. Our sample included persons with tetraplegia and paraplegia; suggesting that the effects of training may have been masked.

The use of low-dose TRT may not suffice to evoke necessary changes in muscle size. Our participants received 2-6 mg of testosterone (average of 4 mg per day) over a 4-month period \[[@R11]\]. Bauman *et al*. used a dose of 5-10 mg per day in hypogonadal men SCI and showed increase in both lean mass and basal metabolic rate following 12 months \[[@R22]\]. Nightingale *et al.* recommended an optimum dose of 6-8 mg per day to increase lean mass in men with SCI \[[@R21]\].

Considering the cost and time of conducting randomized clinical trials, additional data on untrained muscle groups, spasticity, bone architecture and FES-cycling peak VO~2~ were intentionally collected. The original study was not powered based on these outcome variables and possibly type II error (1-β) was committed. The current study may have lacked the necessary power to demonstrate statistical changes in both the trunk and leg muscles. Our main clinical trial was primarily directed towards studying the effects of low dose TRT+RT vs TRT only on muscle size, body composition and visceral adiposity (primary outcome variables) and metabolic profile as determined by the changes in basal metabolic rate, carbohydrate, lipid and inflammatory biomarkers (secondary outcome variables) \[[@R11]\]. Therefore, the findings of the current trial should be treated with caution; because the work is considered a secondary analysis of the untrained muscles; which was not the primary focus of our concluded clinal trial \[[@R11]\]. The findings may be considered as exploratory pilot work that can be effectively used to calculate effect sizes for untrained muscles to adequately power future clinical trials. Pilot studies are of substantial value to gain feasibility and a preliminary indicator of adverse events \[[@R32]\]. The two groups were matched at baseline and adherence to therapies exceeded 95% with very minimal side effects. The preliminary results are promising and a larger powered randomized placebo-controlled trial may be warranted to test the hypothesis and provide firm scientific conclusions.

Conclusion {#S33}
----------

The pilot findings support that 16 weeks of low dose TRT+RT leads to hypertrophy of untrained glutei muscles, which may be of health-related significance considering the prevalence of pressure injuries in this population. The findings support between group differences that favor the effects of TRT+RT compared to the TRT only on the glutei muscles. Additionally, there was a trend towards an interaction between the two groups in the QL and EIO trunk muscles, and no effect was seen on the lower leg muscles. The findings may suggest the need to directly stimulate the trunk muscles or administering a higher dose of TRT to achieve reasonable changes in the size of the trunk muscles. Furthermore, applying and evaluating novel combinatory therapies is warranted given the heterogenous SCI population and the limited effectiveness of single therapies. Overall, these findings may help developing future exercise protocols that can be used to prevent pressure injuries and increase muscle size, thereby improving muscle quality and overall cardio-metabolic health in persons with SCI.
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![Representative MRI images of the analyzed muscle groups which include: gluteus maxumus (1A), gluteus minimus (2A), total glutei (B), erector spinae (1C), multifidus (2C), quadratus lumborum (3C), iliopsoas (4C), rectus abdominus (5C), external and internal obliques (6C), tibialis anterior (1D), soleus (2D), gastrocnemius (3D) and total leg muscles (D).](nihms-1540813-f0001){#F1}

![The mean ± SD of total and absolute gluteus maxiumus (A,B), minimus (C,D) and total muscle (E,F) CSA for the TRT+RT and the TRT only group during BL and PI. \* significant change in muscle CSA at *P*\< 0.05.](nihms-1540813-f0002){#F2}

###### 

Participants' physical and SCI characteristics for the TRT+RT and TRT groups. Values are presented as means ± SD.

  ---------------------------------------------------------
                            TRT+RT (n = 11)   TRT (n = 11)
  ------------------------ ----------------- --------------
        Age (years)              37±12            35±8

       Height (m)- BL            1.8±7           1.8±5

       Height (m)- PI            1.8±7           1.8±5

      Weight (kg)- BL           80.5±16         77.6±10

      Weight (kg)- PI           83.1±16         78.8±10

     BMI (kg/m^2^)- BL          25±4.5          24.0±3.4

     BMI (kg/m^2^)- PI          25±4.7          24.0±3.4

            LOI                 C5-T11           C6-T11

        TSI (years)              10±9             7±6

   ISNCSCI Classification      A (n=8)\         A (n=8)\
                                B (n=3)         B (n=3)

                                             

                                             
  ---------------------------------------------------------

BL: baseline (immediately prior to 16-week interventions); BMI: body mass index; ISNCSCI: International Standards for Neurological Classification of Spinal Cord Injury; LOI: level of injury; PI: post-intervention; RT: resistance training; TSI: time since injury. There were no statistical differences in physical and SCI characteristics between groups at baseline.

###### 

Mean ± SD of individual muscles, IMF CSAs (cm^2^), between group differences and 95% confidence interval (CI) at BL and PI for the TRT+RT and TRT groups.

                                   TRT+RT                        TRT                                                                                      
  ------------ ----------------- ----------- ------------------------------------------- ----------- ----------- ---------------------------------------- ----------------
   **Glutei**     *Total GMX*     23.3±8.0    26.6±9.4[\*](#TFN3){ref-type="table-fn"}    27.2±6.0    27.7±6.2                     2.59                    (−0.04, 5.24)
                *Absolute GMX*    21.8±7.9    25.7±9.4[\*](#TFN3){ref-type="table-fn"}    26.3±5.1    26.9±6.4    2.86^[\#](#TFN4){ref-type="table-fn"}^    (0.30, 5.45)
                   *GMX IMF*       1.3±1.2                     0.8±0.7                     1.3±1.1     0.8±0.6                     0.03                    (−1.09, 1.06)
                  *Total GMD*     23.9±7.0    26.8±8.0[\*](#TFN3){ref-type="table-fn"}    26.3±4.2    26.2±5.2    1.89^[\#](#TFN4){ref-type="table-fn"}^    (0.23, 3.58)
                *Absolute GMD*    22.6±7.3    25.8±7.9[\*](#TFN3){ref-type="table-fn"}    24.8±4.5    25.0±5.6                     1.54                    (−0.45, 3.57)
                   *GMD IMF*       1.4±1.4                     1.0±0.9                     1.5±1.9     1.2±1.1                     0.17                     (−0.86,1.17)
                    *GTOT*        67.0±17.5   73.2±22.0[\*](#TFN3){ref-type="table-fn"}   75.2±7.0     74.2±10    5.27^[\#](#TFN4){ref-type="table-fn"}^    (0.90, 9.69)
                *Absolute GTOT*   56.7±15.6   64.3±18.7[\*](#TFN3){ref-type="table-fn"}   65.1±7.5    66.1±11.2                    4.56                    (−0.23, 9.42)
                  *GTOT IMF*      10.2±5.9                     8.8±5.5                    10.1±3.7     8.0±4.6                     0.9                      (−1.97,3.71)
    **Legs**      *Prox SOL*      14.3±5.0                    15.1±5.0                    14.4±3.1    15.1±3.4                    −0.31                    (−1.93, 1.33)
                   *Mid SOL*      15.0±4.3                    15.2±3.9                    15.3±5.1    15.9±5.0                    −0.87                     (−2.51,0.79)
                  *Dist SOL*       7.8±2.2                     7.5±2.1                    10.1±4.3     9.6±5.0                    −0.02                     (−1.08,1.03)
                *Prox GASTROC*    14.1±3.8                    13.7±3.7                    14.1±5.1    13.7±4.9                    −0.46                     (−1.90,0.99)
                *Dist GASTROC*     9.2±2.8                     9.5±2.8                     9.3±4.9     9.5±4.3                    −0.10                     (−1.07,0.87)
                   *Prox TA*       4.7±1.1                     5.1±1.2                     4.6±1.0     4.8±1.0                     0.40                    (−0.18, 0.97)
                   *Mid TA*        5.9±1.6                     5.9±1.5                     5.7±1.6     5.8±1.7                    −0.05                    (−0.37, 0.26)
                   *Dist TA*       3.0±1.0                     3.1±0.9                     3.4±1.4     3.2±1.1                     0.28                    (−0.22, 0.78)
                  *Prox TLM*      52.5±12.7                   52.6±11.8                   51.5±9.4    51.7±10.2                   −1.52                     (−4.37,1.36)
                   *Mid TLM*       45.4±11                    45.0±9.7                    47.1±15.2   44.9±14.5                    0.56                    (−2.95, −2.55)
                  *Dist TLM*      29.6±6.8                    29.6±7.1                    31.3±11.6    30.5±11                     0.19                    (−2.55, 2.95)
   **Trunk**         *ES*         13.7±4.1                    14.2±4.0                    14.1±3.3    14.4±2.5                     0.20                    (−1.29, 1.68)
                     *MF*          5.5±1.6                     5.8±2.1                     6.0±1.4     6.0±2.4                     0.18                    (−0.75, 1.11)
                     *QL*          4.7±1.7                     5.2±2.1                     5.2±2.5     4.8±2.1                     0.76                    (−0.03, 1.56)
                     *PS*          8.1±3.1                     8.7±2.1                     7.7±2.8     8.1±3.1                    −0.21                    (−1.05, 0.63)
                     *EIO*        20.1±5.5                    20.6±5.7                    19.1±7.2    18.2±6.5                     1.41                    (−0.14, 2.96)
                     *RA*          6.7±1.5                      7.2±2                      5.3±2.8     5.5±2.5                     0.37                    (−0.54, 1.27)

BL: baseline; PI: post-intervention 1; RT: resistance training; TRT: testosterone replacement therapy; GMX: gluteus maximus; GMD: gluteus medius; GTOT: total gluts; IMF: inter-muscular fat; SOL: soleus; GASTROC: gastrocnemius; TA: tibialis anterior; TLM: total leg muscles; ES: erector spinae; MF: multifidus; QL: quadratus lumborum; PS: iliopsoas; EIO: external and internal obliques; RA: rectus abdominus; Prox: proximal; Mid: middle; Dist: distal.

within group differences in the TRT+RT group; *P* \< 0.05.

Mean between group differences, *P*\< 0.05
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